KR910009284A - 인체 종양 세포 항원에 특이적인 키메라형 생쥐-인체 a10 항체 - Google Patents
인체 종양 세포 항원에 특이적인 키메라형 생쥐-인체 a10 항체 Download PDFInfo
- Publication number
- KR910009284A KR910009284A KR1019900018568A KR900018568A KR910009284A KR 910009284 A KR910009284 A KR 910009284A KR 1019900018568 A KR1019900018568 A KR 1019900018568A KR 900018568 A KR900018568 A KR 900018568A KR 910009284 A KR910009284 A KR 910009284A
- Authority
- KR
- South Korea
- Prior art keywords
- fragment
- derivative
- chain
- antibody
- molecule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43501289A | 1989-11-13 | 1989-11-13 | |
US07435012 | 1989-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR910009284A true KR910009284A (ko) | 1991-06-28 |
Family
ID=23726623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900018568A KR910009284A (ko) | 1989-11-13 | 1990-11-13 | 인체 종양 세포 항원에 특이적인 키메라형 생쥐-인체 a10 항체 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0457875A4 (fr) |
JP (1) | JPH03206886A (fr) |
KR (1) | KR910009284A (fr) |
AU (1) | AU634314B2 (fr) |
CA (1) | CA2044590A1 (fr) |
WO (1) | WO1991007418A1 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080407A (en) | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
US5641751A (en) * | 1995-05-01 | 1997-06-24 | Centocor, Inc. | Tumor necrosis factor inhibitors |
WO1997037690A2 (fr) * | 1996-04-10 | 1997-10-16 | Sangstat Medical Corporation | Conjugues cytomodulants d'elements de paires de liaison specifiques |
IT1289608B1 (it) * | 1997-02-05 | 1998-10-15 | Angelini Ricerche Spa | Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
NZ521898A (en) | 2000-03-31 | 2004-11-26 | Purdue Research Foundation | Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response |
EP1578917A4 (fr) | 2001-07-19 | 2008-01-23 | Perlan Therapeutics Inc | Proteines multimeres et methodes de production et d'utilisation de ces proteines |
JP4814520B2 (ja) | 2002-05-15 | 2011-11-16 | エンドサイト,インコーポレイテッド | ビタミン−マイトマイシン結合体 |
EP2517729A3 (fr) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Conjugués d'administration de médicaments à liaison au récepteur de vitamines |
EP1789391B1 (fr) | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Groupes de liaison bivalents et conjugués de ceux-ci |
JP2009504783A (ja) | 2005-08-19 | 2009-02-05 | エンドサイト,インコーポレイテッド | ビンカアルカロイド、類似体および誘導体のリガンド結合体 |
CN103893778A (zh) | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
WO2007092299A2 (fr) | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Conjugués ciblés et radiation |
EP2139523B1 (fr) | 2007-03-14 | 2014-10-22 | Endocyte, Inc. | Conjugés de folate et de tubulysine pour le ciblage d'agents actifs |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
EP3388086B1 (fr) | 2007-08-17 | 2020-10-07 | Purdue Research Foundation | Conjugués comprenant un ligand du psma et un lieur et procédés pour leur utilisation |
AU2008316835B2 (en) | 2007-10-25 | 2015-07-16 | Endocyte, Inc. | Tubulysins and processes for preparing |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
AU2012320597C1 (en) | 2011-10-07 | 2015-10-15 | Baxalta GmbH | oxMIF as a diagnostic marker |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
MX2015004757A (es) | 2012-10-16 | 2015-07-17 | Endocyte Inc | Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos. |
CN108042811A (zh) | 2012-11-15 | 2018-05-18 | 恩多塞特公司 | 用于治疗由psma表达细胞引起的疾病的共轭物 |
LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
CN107847609A (zh) | 2015-03-13 | 2018-03-27 | 恩多塞特公司 | 用于治疗疾病的缀合物 |
TW202304518A (zh) | 2021-04-16 | 2023-02-01 | 瑞士商諾華公司 | 葉酸受體靶向性放射治療劑及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
AU625613B2 (en) * | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
GB8800078D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel antibodies |
IL89489A0 (en) * | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
-
1990
- 1990-11-13 WO PCT/US1990/006620 patent/WO1991007418A1/fr not_active Application Discontinuation
- 1990-11-13 AU AU66641/90A patent/AU634314B2/en not_active Ceased
- 1990-11-13 EP EP19910900650 patent/EP0457875A4/en not_active Withdrawn
- 1990-11-13 KR KR1019900018568A patent/KR910009284A/ko not_active Application Discontinuation
- 1990-11-13 JP JP2308453A patent/JPH03206886A/ja active Pending
- 1990-11-13 CA CA002044590A patent/CA2044590A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0457875A4 (en) | 1993-03-03 |
AU634314B2 (en) | 1993-02-18 |
AU6664190A (en) | 1991-05-23 |
WO1991007418A1 (fr) | 1991-05-30 |
CA2044590A1 (fr) | 1991-05-14 |
EP0457875A1 (fr) | 1991-11-27 |
JPH03206886A (ja) | 1991-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910009284A (ko) | 인체 종양 세포 항원에 특이적인 키메라형 생쥐-인체 a10 항체 | |
AU627183B2 (en) | Method for producing recombinant dna proteins | |
FI935795A (fi) | Ctl4a-receptor, fusionsproteiner innehaollande denna och anvaendningar daerav | |
IL108374A (en) | Methods and compositions for regulating the immune response using CTLA4-binding molecules and IL4-binding molecules | |
KR900700606A (ko) | Ig-cd4융합 단백질을 코드화하는 클론된 유전자 및 그의 이용 | |
CA2188422A1 (fr) | Proteine a double fonction, sa preparation et son utilisation | |
AU2659488A (en) | Transfectant cell lines which express the major human rhinovirus receptor | |
CN103728447B (zh) | 可控量子点位点特异性桥接偶联的抗体标记方法及其应用 | |
IE870487L (en) | Lung carcinoma antigen and antibody | |
WO2003000176A2 (fr) | Conjugues d'anticorps reduits et biomolecules | |
US5965405A (en) | Method for producing Fv fragments in eukaryotic cells | |
Segal et al. | Production of bispecific antibodies | |
Lansdorp et al. | Purification and analysis of bispecific tetrameric antibody complexes | |
Williams | Novel antibody reagents: production and potential | |
Creveling et al. | Immunological characterization of catechol-O-methyltransferase | |
KR930701620A (ko) | 재조합 dna 백터를 이용하여 인체 t-세포 리셉터 성분에 대한 단일 클론성 항체의 제조방법 | |
CA2019323A1 (fr) | Anticorps km10 chimeriques humain - murin specifiques contre un antigene de cellules tumorales humaines | |
US7067314B2 (en) | Monoclonal antibody, its immunoreactive fragment and hybridoma | |
EP4342908A1 (fr) | Immunoglobuline chimérique | |
CA2142171A1 (fr) | Adn recombinant codant pour un anticorps, et son usage | |
CA1329545C (fr) | Complexe immunologique, sa preparation et son usage | |
WO1991005856A1 (fr) | ANTICORPS MONOCLONAUX CHIMERIQUES GENERES PAR RACCORDEMENT $i(TRANS) | |
Brimijoin et al. | Immunochemical approaches to the study of mammalian cholinesterases | |
Marchalonis et al. | Introduction—The Immunoglobulin-Like T Cell Receptor Problem | |
UY25943A1 (es) | Proteínas de fusión ctla4 ig" para regular las interacciones celulares y las respuestas inmunitarias. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |